iNtRON developed advanced bacteriophage engineering platform technology based on modified random mutagenesis
The transposon technology development following the customized CRISPR/Cas system for bacteriophage 2nd Generation technology of Robot Bacteriophage BOSTON and SEOUL, South Korea, Oct. 18, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) has announced today that the Company has established the 2nd generation technology of Robot Bacteriophage development. The random transposon mutagenesis technology can be now applied...
Axiomtek Unleashes IP69K/IP66-Rated 10.4″ Stainless Steel Fanless Touch Panel Computer for Food Processing Industry – GOT810-316
TAIPEI, Oct. 18, 2022 /PRNewswire/ -- Axiomtek – a world-renowned leader relentlessly devoted in the research, development and manufacture of series of innovative and reliable industrial computer products of high efficiency – is pleased to announce the GOT810-316, a 10.4-inch stainless steel fanless touch panel computer for the food, beverage, and pharmaceutical industries. To withstand high-pressure...
InxMed Releases Data Demonstrating IN10018 Therapeutic Potential in Patients with Metastatic Melanoma at SMR 2022
NANJING, China, Oct. 18, 2022 /PRNewswire/ -- InxMed Co., Ltd, a clinical-stage biotechnology company dedicated to developing innovative therapies targeting drug resistance for hard-to-treat solid tumors, is pleased to announce that the clinical data from an open-label, phase Ib trial evaluating the efficacy and safety of IN10018, a highly potent and selective oral...
GenScript ProBio Signs MOU to Form Strategic Partnership with GeneCraft To Development and Production of New AAV gene therapies
SEOUL, South Korea, Oct. 18, 2022 /PRNewswire/ -- On the Oct 17, 2022, GenScript ProBio (Brian Ho-sung Min, CEO), a global CDMO, and GeneCraft (Suk Chul Bae, CEO), a global research team led by Professor Suk Chul Bae of lung cancer mechanism research, announced that they had entered into a strategic partnership MOU concerning the development and production of a new drugs needed...
ICBE-EMF Submits: Wireless Technology Not Adequately Assessed for Hazards to Human Health and Environment
New peer-reviewed paper presents scientific case for revision of limits TUCSON, Ariz., Oct. 18, 2022 /PRNewswire/ -- The International Commission on the Biological Effects of Electromagnetic Fields (ICBE-EMF) is challenging the safety of current wireless exposure limits to radiofrequency radiation (RFR) and is calling for an independent evaluation. Published today in the journal Environmental Health, "Scientific evidence invalidates health assumptions underlying...
TLX250-CDx Indication Expansion: Preliminary Data Presented at EANM
OPALESCENCE Phase II feasibility study of TLX250-CDx in patients with triple-negative breast cancer – early results suggest potential to detect carbonic anhydrase IX (CAIX) expression, theranostic potential in this difficult to treat disease. PERTINENCE Early Phase I feasibility study of TLX250-CDx in patients with non-muscle-invasive bladder cancer, a collaboration with ATONCO...
GenScript ProBio Enters Strategic Collaboration with Hibiocy Co. Ltd, the affiliate of Rojukiss International Public Company Limited (KISS) – the leading Thai-based Beauty & Health company, for the development...
SINGAPORE, Oct. 17, 2022 /PRNewswire/ -- GenScript ProBio (a global one-stop CDMO from GenScript Group) today announced a strategic collaboration with Hibiocy Co. Ltd., a private corporation based in Bangkok, Thailand, to accelerate a respiratory-care medical device, COVITRAP™ which contains human antibody for Covid-19 inhibiting project. COVITRAP™ is a nasal spray which is...
Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia
Clinical trial assessing allogeneic, HLA-matched, donor-derived allogeneic CAR-T therapy SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Oct. 17, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that the...
PharmAbcine Announces Poster Presentations on Its anti-VISTA Antibody Candidate at SITC 2022
DAEJEON, South Korea, Oct. 17, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the Company will present preclinical data of PMC-309, one of the Company's first immuno-oncology drug candidates, at SITC (Society for Immunotherapy of Cancer) Annual Meeting taking place November 8-12 in Boston. ...
Value of Tissue Analytics for Remote Care Highlighted in Research From Australian Virtual Wound Care Program
PITTSBURGH and SYDNEY, Oct. 17, 2022 /PRNewswire/ -- Net Health, a leading provider of specialty electronic health record (EHR) systems and advanced healthcare analytics, announced results from a first-of-its-kind study for a promising wound care treatment model. The findings showed Net Health® Tissue Analytics, the company's AI-powered wound imaging and analysis...
